Clinical trialPhase 1 / Phase 2Active not recruiting
Study of LP-184 in Patients With Advanced Solid Tumors
A Phase 1/2 Dose Escalation and Cohort Expansion Study of LP-184 in Patients With Advanced or Metastatic Solid Tumors
- Outcome
- Ongoing
- Phase
- Phase 1 / Phase 2
- Status
- Active not recruiting
- Study type
- Interventional
- Start
- 9 June 2023
- Listed end
- 28 July 2026
- Enrollment
- 64 participants
- Sites
- 7
- Primary outcomes
- To evaluate the safety and tolerability of LP-184 assessed by the incidence and severity of all adverse events graded by CTCAE v5.0; To determine the MTD of LP-184 based on all available safety (graded by CTCAE v5.0) and PK data.; To determine the RP2D of LP-184 based on all available safety (graded by CTCAE v5.0), PK, PD and efficacy data
- Sponsor type
- Industry
- Results posted
- No
- Last update
- 4 May 2026
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
The primary objective of this study is to evaluate the safety, tolerability, MTD and RP2D of LP-184 in patients with advanced solid tumors who have relapsed from or are refractory to standard therapy or for whom no standard therapy is available. The secondary objectives are to characterize the PK of LP-184 and its metabolites in plasma and assess clinical activity of LP-184. Participants will receive LP-184 infusion during Day 1 and Day 8 of each 21-day cycle, for a minimum of two cycles. Patients will be monitored for safety, PK, and clinical activity
Detailed description public domain (ClinicalTrials.gov)
Patients who meet all eligibility criteria will be enrolled to receive treatment with LP-184 at a dose determined based on the available cohort at the time of each patient's enrollment. Patients will receive LP-184 infusion during Day 1 and Day 8 of each 21-day cycle, for a minimum of two cycles. Patients will be monitored for safety, PK, and clinical activity. Dose escalation is planned with minimum of 3 patient cohorts (starting at dose level 1). After selection of the maximum tolerated dose (MTD), additional patients will be enrolled at two dose levels, including the MTD, as determined by the Safety Review Committee, until at least 10 patients each are treated at each dose to determine the recommended phase 2 dose.
Papers 3
- Builds on itPhase Ia Evaluation of LP-184 in Recurrent Glioblastoma: Safety, Pharmacokinetics, and Translational Optimization of CN… DOI 10.1158/2767-9764.crc-26-0518↗
- Builds on itQuantitative characterization of platelet count and alanine aminotransferase dynamics to inform personalized dosing in … DOI 10.1007/s00280-026-04937-2↗
- Builds on itA first-in-human phase 1a study of LP-184, a tumor-site activated novel alkylating agent, in patients with advanced sol… DOI 10.1007/s10637-026-01626-y↗